TMC Life Sciences Berhad (KLSE:TMCLIFE) Full Year 2024 Results

Key financial results

• Revenue: RM346.4 million (an increase of 11% over FY2023).

• Net income: RM40.6 million (an increase of 3.5% over FY2023).

• Profit margin: 12% (in line with FY 2023).

• EPS: RM0.023 (in line with FY2023).

All figures shown in the graph above refer to the last 12 months (TTM)

TMC Life Sciences Berhad shares fell 4.9% compared to the previous week.

Balance sheet analysis

Although it is very important to consider the income statement, you can also learn a lot about a company by looking at its balance sheet. We have done some analysis and You can see our assessment of TMC Life Sciences Berhad’s balance sheet.

Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.